再鼎醫藥-SB(9688.HK)高開超10% 自願轉換為雙重主要上市 下週一生效
格隆匯6月23日丨再鼎醫藥-SB(9688.HK)高開10.61%報24.5港元,市值240億港元。公司宣佈自願將其於聯交所的第二上市地位轉換為雙重主要上市,於下週一(27日)生效,公司將成為於聯交所及納斯達克全球市場雙重主要上市的公司,且將自股票簡稱中刪除標記“S”。注:雙重上市是完全滿足兩地監管要求,和本地上市沒有太大區別,更容易被國際投資者接受,也更易於符合A股市場監管納入港股通。從公司的角度來講,雙重上市擴大了其股東基礎,提升了全球市場的影響力,從而使公司可以在其他證券市場上進行融資,並進一步將業務擴展到其他市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.